Fig. 4From: Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrheaMonthly responder rates for improvement in stool consistency. Height: responder rate (%). Error bar: 95% CI. P values were calculated using the χ 2-test as follows: ***P < 0.001, **P < 0.01, and *P < 0.05Back to article page